Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-Current Deffered Revenue: 2017-2018

Historic Non-Current Deffered Revenue for Rocket Pharmaceuticals (RCKT) over the last 2 years, with Dec 2018 value amounting to $457,000.

  • Rocket Pharmaceuticals' Non-Current Deffered Revenue rose 327.10% to $457,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $457,000, marking a year-over-year increase of 327.10%. This contributed to the annual value of $457,000 for FY2018, which is 327.10% up from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Non-Current Deffered Revenue stood at $457,000 for FY2018, which was up 327.10% from $107,000 recorded in FY2017.
  • Rocket Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $457,000 for FY2018, and its period low was $107,000 during FY2017.
  • Its 2-year average for Non-Current Deffered Revenue is $282,000, with a median of $282,000 in 2017.
  • Data for Rocket Pharmaceuticals' Non-Current Deffered Revenue shows a peak YoY spiked of 327.10% (in 2018) over the last 5 years.
  • Yearly analysis of 2 years shows Rocket Pharmaceuticals' Non-Current Deffered Revenue stood at $107,000 in 2017, then surged by 327.10% to $457,000 in 2018.